Krystal Biotech, Inc. — Director's Dealing 2017

Sep 25, 2017

SEC Form 3/A — Form 3/A

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2017-09-19

Reporting Person: JANNEY DANIEL (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	130590	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (124456)		Indirect
Stock Option (Right to Buy)	$2.46	2026-11-09	Common Stock (37894)		Direct

Footnotes

F1: These shares were incorrectly reported as being owned directly in the reporting person's original Form 3, filed September 19, 2017.

F2: Directly beneficially owned by Alta Bioequities, L.P.

F3: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The reporting person is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F4: The Series A convertible preferred stock will automatically convert on a one-to-one basis into 124,456 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.

F5: These shares were incorrectly included in the Non-Derivative Securities table in the reporting person's original Form 3, filed September 19, 2017.

F6: The options were awarded on November 10, 2016 and vest ratably over a four-year period.

F7: The exercise price was incorrectly reported in the reporting person's original Form 3, filed September 19, 2017.